Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that management will participate in a fireside chat and host investor meetings at the JMP Securities Life Sciences Conference being held May 15-16, 2023 at the New York Hilton Midtown in New York, NY.

The JMP Securities Life Sciences Conference
Date: Tuesday, May 16, 2023
Time: 11:00 a.m. ET

About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the prevention of recurrent C. difficile infection, inflammatory bowel diseases, food allergy, and liver disease. These investigational therapies are grounded in our team’s pioneering research – published in leading journals including Science, Nature, Cell, and JAMA – to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens, and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 70 patents and has built what it believes is the industry-leading platform for development of defined bacterial consortia drugs. This platform includes one of the largest libraries of bacteria derived from the human microbiome, vast datasets from human interventional studies, proprietary capabilities in consortium design, and end-to-end capabilities for CGMP-compliant manufacturing of oral drug candidates spanning cell banking, fermentation, lyophilization, and fill finish.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005388/en/

Media
Nichole Sarkis
+1 774 278 8273
[email protected]

Investors
Chris Brinzey
+ 1 617 835 9304
[email protected]

Source: Vedanta Biosciences

You May Also Be Interested In

• Deep Fission Rejects Distortions in Short-Seller Report
• Could $0.00055 Make Apeing the Best Crypto to Buy Now? KOLs Take Notice as BCH Jumps and HYPE Launches New Data
• Florida DTF Transfer Printer Launches Heat Press Kits After Customer Reviews Show New Press Owners Unsure What to Buy Next